E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Patients with mild to moderate chronic renal failure (CRF; GFR 15-60ml/min; n=26) Patients with mild to moderate CRF and coexisting Diabetes Mellitus (n=26)
|
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064848 |
E.1.2 | Term | Chronic kidney disease |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 12.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10045242 |
E.1.2 | Term | Type II diabetes mellitus |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The major goal of this study is to develop an enhanced understanding of the disturbances involved in how a progressive loss of kidney function cause increased cardiovascular disturbance, disease and ultimately death, and if some of these disturbances can be ameliorated and modified by treatment with a VDRA. Furthermore, evidence suggest that Diabetic kidney disease constitute a separate entity with certain characteristics that may respond differently to treatment with VDRA. Thus we intend to compare diabetic kidney disease with non-diabetic. As kidney disease is characterized by increased neurohormonal activation and sympathetic overactivity, the primary outcome variable will be a change (reduction) in sympathetic activity as measured by a tungsten microelectrode inserted percutaneously into a fascicle of the peroneal nerve at the level of the fibular head (muscle sympathetic nerve activity: MSNA).
|
|
E.2.2 | Secondary objectives of the trial |
A) To determine whether sympathetic overactivity cause sympathovagal imbalance, reflected in altered heart rate variability, disturbed baroreflex regulation, and altered transfer-function between blood pressure and sympathetic nerve activity? May these disturbances be ameliorated by treatment with VDRA? B) Endothelial dysfunction and increased arterial stiffness are common features in severe renal failure, and have been shown even before diagnosis in DM-II. To which degrees are they present in mild to moderate CKD, and how do they correlate with other physiological changes? May these disturbances be modified by treatment with VDRA? C/ Several factors involved in haemostasis and inflammation are independent risk factors for mortality in patients with end stage renal disease. Is the haemostasis disturbed in mild to moderate CKD, and if so, is this correlated to sympathetic activation and impaired microcirculatory control? May these disturbances be ameliorated by treatment with VDRA? |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Man or woman above 20 years of age. If woman in reproductive age: not nursing and not pregnant (preseting a negative pregnancy test), and on anticonception therapy. Calculated GFR between 15-59 mL/min/1.73m2 using MDRD S-Ca2+ <2.6 mmol/L iPTH between 35-500 pg/mL Serum albumin > 3.0 g/dL Signed informed consent
For inclusion in the diabetes study group: • Diagnosed type II diabetes, and treated with peroral antidiabetics or insulin the last 12 months • HbA1c <= 12%
|
|
E.4 | Principal exclusion criteria |
Changes in ACE-inhibitor medication or ARB within 8 weeks before start of the study.
Nefrotic syndrome Expected need for dialysis within 6 months after study start Vitamin D treatment within 6 months before start of the study. Poorly controlled hypertension with blood pressure >150/100 mmHg (repeated measurements after 15 minutes rest) Concomitant treatment with drugs affecting bone and calcium metabolism such as kalcitonin, cinacalcet (Mimpara or Parareg), and high dose corticosteroids. Concomitant treatment with drugs inhibiting or inducing Cytokrom P450 3A. Known hypersensitivity to any of the substances in study drug or placebo. Diabetic nefropathy and concurrent glomerulonefritis or nefritis Acute renal failure within 12 weeks before screening Other severe chronic disease (AIDS/HIV-positive, cancer, severe heart failure etc.) Known kidney artery stenosis Known kidney stone disease Intake of other investigational medicinal product within 30 days before screening. Known alcohol or drug abuse Known low compliance Not suitable for participation for other reason according to investigators opinion.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Sympathetic activation measured by microneurography at the conclusion of the 12 weeks treatment period. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Study of patophysiological mechanisms. |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last subject undergoing the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 6 |